Sabra Healthcare REIT had its Relative Strength (RS) Rating upgraded from 80 to 85 Friday.
IBD's proprietary rating measures share price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains often have an 80 or higher RS Rating in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Sabra Healthcare REIT is still within a buy range after moving past a 19.32 entry in a flat base. The proper buying range extends to 5% above the initial entry. Once a stock hits that benchmark, it's best to wait for it to set up another buying opportunity.
Regarding fundamentals, the company has posted rising EPS growth in each of the last three reports. Top line growth has also moved higher during the same period.
The company earns the No. 10 rank among its peers in the Finance-Property REITs industry group. CareTrust REIT, American Assets Trust and COPT Defense Properties are among the top 5 highly rated stocks within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
